Sporadic desmoid-type fibromatosis: A stepwise approach to a non-metastasising neoplasm-A position paper from the Italian and the French Sarcoma Group

Annals of Oncology

Volumn 25, Issue 3, 2014, Pages 578-583

  Gronchi, A ^a   Colombo, C ^a   Le Pechoux C ^b   Dei Tos, A P ^c   Le Cesne, A ^b   Marrari, A ^a   Penel, N ^d   Grignani, G ^e   Blay, J Y ^f   Casali, P G ^a   Stoeckle, E ^g   Gherlinzoni, F ^h   Meeus, P ^f   Mussi, C ⁱ   Gouin, F ^j   Duffaud, F ^k   Fiore, M ^a   Bonvalot, S ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c Treviso General Hospital   (Italy)

^d CENTRE OSCAR LAMBRET   (France)

^e CANDIOLO CANCER INSTITUTE   (Italy)

^f CENTRE LÉON BÉRARD   (France)

^g INSTITUT BERGONIÉ   (France)

^h Ospedale Civile di Gorizia   (Italy)

ⁱ HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^j NANTES UNIVERSITY HOSPITAL   (France)

^k AIX MARSEILLE UNIVERSITY   (France)

more..

Author keywords

Aggressive fibromatosis; Desmoid tumor; Medical therapy; Outcome; Radiation therapy; Surgery; Wait and see approach

Indexed keywords

CATENIN; WNT PROTEIN;

ALGORITHM; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL FEATURE; ETHNIC GROUP; FIBROMATOSIS; FRENCH LANGUAGE; HUMAN; ITALIAN; MYOFIBROBLAST; PATHOGENESIS; PATIENT COUNSELING; PREVALENCE; PRIORITY JOURNAL; REVIEW; SARCOMA; SPORADIC DESMOID TYPE FIBROMATOSIS; WNT SIGNALING PATHWAY;

AGGRESSIVE FIBROMATOSIS; DESMOID TUMOR; MEDICAL THERAPY; OUTCOME; RADIATION THERAPY; SURGERY; WAIT AND SEE APPROACH;

BETA CATENIN; FIBROMATOSIS, AGGRESSIVE; FRANCE; HUMANS; ITALY; NEOPLASM RECURRENCE, LOCAL; WATCHFUL WAITING; WNT SIGNALING PATHWAY;

EID: 84896895776     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt485     Document Type: Review

References (53)

1. Fletcher JA, Bridge JA, Hogendoorn PCW et al. Desmoid-type fibromatoses. In WHO Classification of Tumors of Soft Tissue and Bone. Lyon: IARC Press 2013; 72-73.
2. Clark SK, Phillips RKS. Desmoids in familial adenomatous polyposis. Brit J Surg 1996; 83: 1494-1504.
3. de Bree E, Keus R, Melissas J et al. Desmoid tumors: need for an individualized approach. Expert Rev Anticancer Ther 2009; 9(4): 525-535.
4. Stone JH, Zen Y, Deshpande V. Igg4 related disease. N Engl J Med 2012; 366(6): 539-551.
5. Carothers AM, Rizvi H, Hasson RM et al. Mesenchymal stromal cell mutations and wound healing contribute to the etiology of desmoid tumors. Cancer Res 2012; 72 (1): 346-355.
6. Deyrup AT, Tretiakova M, Montag AG. Estrogen receptor-β expression in extraabdominal fibromatoses-an analysis of 40 cases. Cancer 2006; 106: 208-213.
7. Amini Nika S, Ebrahima RP, Van Dama K et al. TGF-β modulates β-catenin stability and signaling in mesenchymal proliferations. Exp Cell Res 2007; 313: 2887-2895.
8. Cheon SS, Cheah AYL, Turley S et al. β-Catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds. Proc Natl Acad Sci USA 2002; 10: 6973-6978.
9. Bennet NT, Schultz GS. Growth factors and wound healing; biochemical properties of growth factors and their receptors. Am J Surg 1993; 165: 728-737.
10. Alman BA, Li C, Pajerski ME et al. Increased β-catenin and somatic mutations in sporadic aggressive fibromatosis (desmoids tumors). Am J Pathol 1997; 151: 329-334.
11. Lazar AJ, Tuvin D, Hajibashi S et al. Specific mutations in β-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 2008; 173: 1518-1527.
12. Kotiligam D, Lazar AJ, Pollock RE et al. Desmoid tumor: a disease opportune for molecular insights. Histol Histopathol 2008; 23: 117-126.
13. Reitamo JJ, Sheinin TM, Pekka H. The desmoid syndrome. New aspects in the cause, pathogenesis and treatment of the desmoid tumor. Am J Surg 1986; 15: 230-237.
14. Spear MA, Jennings LC, Mankin HJ et al. Individualizing management of aggressive fibromatoses. Int J Radiat Oncol Biol Phys 1998; 40(3): 637-645.
15. Merchant NB, Lewis JJ, WoodruffJM et al. Extremity and trunk desmoid tumors: a multifactorial analysis of outcome. Cancer 1999; 86(10): 2045-2052.
16. Janinis J, Patriki M, Vini L et al. The pharmacological treatment of aggressive fibromatosis: a systemic review. Ann Oncol 2003; 14: 181-190.
17. de Camargo VP, Keohan ML, D'Adamo DR et al. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer 2010; 116 (9): 2258-2265.
18. Bonvalot S, Eldweny H, Haddad V et al. Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol 2008; 34(4): 462-468.
19. Fiore M, Rimareix F, Mariani L et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol 2009; 16(9): 2587-2593.
20. Bonvalot S, Desai A, Coppola S et al. The treatment of desmoid tumors: a stepwise clinical approach. Ann Oncol 2012; 23(Suppl 10): x158-x166.
21. Colombo C, Gronchi A. Desmoid-type fibromatosis: what works best? Eur J Cancer 2009; 45(Suppl 1): 466-467.
22. Stojadinovic A, Leung DH, Hoos A et al. Analysis of prognostic significance of microscopic margins in 2084 localized primary adult soft tissue sarcomas. Ann Surg 2002; 235(3): 424-434.
23. Zagars GK, Ballo MT, Pisters PW et al. Prognostic factors for patients with localized soft tissue-sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer 2003; 97(10): 2530-2543.
24. Gronchi A, Casali PG, Mariani L et al. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of 911 consecutive patients treated at a single institution. J Clin Oncol 2005; 23(1): 96-104.
25. Ballo MT, Zagars GK, Pollack A et al. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 1999; 17: 158-167.
26. Gronchi A, Casali PG, Mariani L et al. Quality of surgery and outcome in extraabdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol 2003; 21: 1390-1397.
27. Lev D, Kotilingam D, Wei C et al. Optimizing treatment of desmoid tumors. J Clin Oncol 2007; 25(13): 1785-1791.
28. Salas S, Dufresne A, Bui B et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol 2011; 29(26): 3553-3558.
29. Nuyttens JJ, Rust PF, Thomas CR et al. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors. A comparative review of 22 articles. Cancer 2000; 88: 1517-1523.
30. Guadagnolo BA, Zagars GK, Ballo MT. Long-term outcomes for desmoid tumors treated with radiation therapy. Int J Radiat Oncol Biol Phys 2008; 71: 441-447.
31. Keus R, Nout RA, Blay JY et al. Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis-an EORTC STBSG and ROG study (EORTC 62991-22998). Ann Oncol 2013; 24(10): 2672-2676.
32. Pignatti G, Barbanti-Brodano G, Ferrari D et al. Extraabdominal desmoid tumor. A study of 83 cases. Orthop Relat Res 2000; 375: 207-213.
33. Rock MG, Pritchard DJ, Reiman HM et al. Extra-abdominal desmoid tumors. J Bone Joint Surg Am 1984; 66: 1369-1374.
34. Lewis JJ, Boland PJ, Leung DH et al. The enigma of desmoid tumors. Ann Surg 1999; 229: 866-872.
35. Phillips SR, A'Hern R, Thomas JM. Aggressive fibromatosis of the abdominal wall, limbs and limb girdles. Br J Surg 2004; 91: 1624-1629.
36. Colombo C, Miceli R, Lazar A et al. CTNNB1 45f mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent multicenter validation study. Cancer 2013. doi: 10.1002/cncr.28271
37. Skapek SX, Anderson JR, Hill DA et al. Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a children's oncology group (COG) phase II study. Pediatr Blood Cancer 2013; 60(7): 1108-1112.
38. Fiore M, Colombo C, Radaelli S et al. Activity of toremifene in sporadic desmoidtype fibromatosis. J Clin Oncol 2011; 29(Suppl): abstr 10033.
39. Azzarelli A, Gronchi A, Bertulli R et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer 2001; 92(5): 1259-1264.
40. Weiss AJ, Horowitz S, Lackman RD. Therapy of desmoid tumors and fibromatosis using vinorelbine. Am J Clin Oncol 1999; 22(2): 193-195.
41. Skapek SX, Ferguson WS, Granowetter L et al. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a pediatric oncology group phase II trial. J Clin Oncol 2007; 25(5): 501-506.
42. Garbay D, Le Cesne A, Penel N et al. Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol 2012; 23(1): 182-186.
43. Constantinidou A, Jones RL, Scurr M et al. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer 2009; 45(17): 2930-2934.
44. Patel SR, Benjamin RS. Desmoid tumors respond to chemotherapy: defying the dogma in oncology. J Clin Oncol 2006; 24(1): 11-12.
45. Bonvalot S, Rimareix F, Causeret S et al. Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient. Ann Surg Oncol 2009; 16(12): 3350-3357.
46. Kujak JL, Liu PT, Johnson GB et al. Early experience with percutaneous cryoablation of extra-abdominal desmoid tumors. Skeletal Radiol 2010; 39: 175-182.
47. Walczak BE, Rose PS. Desmoid: the role of local therapy in an era of systemic options. Curr Treat Options Oncol 2013; 14(3): 465-473.
48. Heinrich MC, McArthur GA, Demetri GD et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006; 24: 1195-1203.
49. Penel N, Le Cesne A, Bui BN et al. Imatinib for progressive and recurrent aggressive fibromatosis (demoid tumors): an FNCLCC/French Sarcoma Group phase II trial with long-term follow up. Ann Oncol 2011; 22: 452-457.
50. Chugh R, Wathen JK, Patel SR et al. Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter sarcoma alliance for research through collaboration (SARC) trial. Clin Cancer Res 2010; 16(19): 4884-4891.
51. Gounder MM, Lefkowitz RA, Keohan ML et al. Activity of sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res 2011; 17(12): 4082-4090.
52. Bonvalot S, Ternes N, Fiore M et al. Spontaneous regression of primary abdominal wall desmoids: more common than previously thought. Ann Surg Oncol 2013; doi: 10.1245/s10434-013-3197-x.
53. Fiore M, Coppola S, Cannell AJ et al. Desmoid-type fibromatosis and pregnancy. A multi-institutional analysis of recurrence and obstetric risk. Ann Surg 2013; doi: 10.1097/SLA.0000000000000224.